Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

1. Dramatic Decrease in Prostate Cancer and

2. Major Reduction in Need For BPH Prostate Surgery

HASBROUCK HEIGHTS, N.J., Aug. 29, 2016 -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, has been found after 7 years of prospective placebo controlled double blind studies of treatment of 995 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. This is in stark contrast to some conventional BPH treatments in routine clinical use today which on the other hand increase prostate cancer risk, and which have many other well-known undesirable side effects such as retrograde ejaculation which is when men lose the ability to have normal orgasms.

Published: 29 August 2016

Written by Editor

Nasdaq Project Update

Leap Therapeutics and Macrocure Announce Definitive Merger Agreement

CAMBRIDGE, Massachusetts and PETACH TIKVA, Israel, August 29, 2016 -- Leap Therapeutics, Inc., a clinical stage immuno-oncology company, and Macrocure Ltd. (MCUR) today announced the signing of a definitive merger agreement. Under the terms of the agreement, Macrocure will become a wholly owned subsidiary of Leap, and Leap will become a public company. In connection with the transaction, Leap will apply to have the shares of the combined entity listed for trading on NASDAQ upon completion of the merger.

Under the terms of the agreement, Macrocure shareholders will exchange their Macrocure shares for newly issued shares of Leap common stock. In addition, existing Leap investors, including entities affiliated with HealthCare Ventures, have committed to invest an additional $10 million at the closing of the transaction.

Published: 29 August 2016

Written by Editor

Nasdaq M & A Up on News

Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program With DPX-Survivac in Ovarian Cancer

HALIFAX, NOVA SCOTIA--(Aug 25, 2016) - Immunovaccine Inc. (IMV.TO)(IMMVF), a clinical stage vaccine and immunotherapy company, today announced new data from its Phase 1/1b trial in ovarian cancer, which reinforced previously reported results showing that DPX-Survivac was well tolerated, with no unexpected treatment-related serious adverse events (SAEs) and that it demonstrated the ability to generate a relevant, sustained immune response.

New data from the Phase 1/1b trial yielded positive findings on tumor clinical response-including the presence of relevant circulating T cells and increased expression of several checkpoint inhibitor molecules. New analyses from the trial indicated:

Targeted T cell responses to survivin, the DPX-Survivac target protein, were observed in 87 percent of study participants evaluable for immune response (47 of 54 evaluable patients)

Published: 25 August 2016

Written by Editor

TSX Up on News Project Update

Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401

NEW YORK, Aug. 23, 2016 -- Stemline Therapeutics, Inc. (STML) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to SL-401, a targeted therapy directed to the interleukin-3 receptor (CD123), for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

The FDA’s Breakthrough Therapy Designation is intended to expedite the development and review of a drug candidate for serious or life-threatening conditions. The criteria for Breakthrough Therapy Designation require clinical evidence demonstrating the drug may offer substantial improvement on one or more clinically significant endpoints versus existing therapies.

This Breakthrough Designation request was supported by efficacy and safety data from the Phase 2 trial evaluating SL-401 in BPDCN patients in both the first-line and relapsed/refractory settings.

Published: 23 August 2016

Written by Editor

Nasdaq FDA HC Decision Up on News

Pfizer to Acquire Medivation

NEW YORK, NY and SAN FRANCISCO, CA --(August 22, 2016) -Medivation, Inc. (NASDAQ: MDVN) -

Propels Pfizer into a leading position in oncology ---- Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion ---- Expected to be immediately accretive to Pfizer's Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth anticipated thereafter

Pfizer Inc. (PFE) and Medivation, Inc. (MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer's Adjusted Diluted EPS upon closing, approximately $0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance.

Published: 22 August 2016

Written by Editor

M & A Up on News biotech

Nymox Pharmaceutical Corp. ( NYMX )

Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

Macrocure Ltd ( MCUR )

Leap Therapeutics and Macrocure Announce Definitive Merger Agreement

Immunovaccine Inc ( IMV )

Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program With DPX-Survivac in Ovarian Cancer

Stemline Therapeutics Inc ( STML )

Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401

Medivation Inc ( MDVN )

Pfizer to Acquire Medivation